SPY421.97-0.14 -0.03%
DIA338.65-2.11 -0.62%
IXIC14,161.35+121.67 0.87%

TG Therapeutics Posts Wider Q1 Loss, Revenue Higher

05/10/2021 04:12

08:07 AM EDT, 05/10/2021 (MT Newswires) -- TG Therapeutics (TGTX) on Monday reported a Q1 net loss of $0.69 per share, compared with a loss of $0.48 per share in the previous year.

Analysts polled by Capital IQ were expecting a net loss of $0.54 per share.

Revenue amounted to $793,000, up from $38,000 a year ago. Analysts were expecting revenue of $830,000.

The biopharmaceutical firm said that it plans to submit a biologic license application for ublituximab for the treatment of patients with relapsing forms of multiple sclerosis in Q3. It also plans to commence enrollment in ULTRA-V Phase 3 trial evaluating the triple combination of Ukoniq plus venetoclax in chronic lymphocytic leukemia.

Price: 40.00, Change: -0.20, Percent Change: -0.50